Trilantic North America, a growth-focused middle market private equity firm, announces that it has made a substantial growth investment in SOFIE Biosciences (“SOFIE” or the “Company”), a founder-led radiopharmacy and contract development and manufacturing organization. Headquartered in Dulles, Virginia and with 15 locations across the United States, SOFIE is a leading player in the radiopharmaceutical sector, manufacturing more than 567,000 doses annually on behalf of its partners and customers. The growth investment from Trilantic North America will capitalize the business to execute on several growth initiatives, including expanding capacity and points of presence to improve patient access to its growing portfolio of radiopharmaceutical products.
Read the full article: Trilantic North America Completes Strategic Growth Investment in SOFIE Biosciences //
Source: https://www.businesswire.com/news/home/20240604387681/en/Trilantic-North-America-Completes-Strategic-Growth-Investment-in-SOFIE-Biosciences